Old Web
English
Sign In
Acemap
>
authorDetail
>
E. Douglass
E. Douglass
University of Chicago
Medicine
Urine
Dosing
Pathology
Thymidylate synthase inhibitor
3
Papers
35
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I Study of ZD9331 on Short Daily Intravenous Bolus Infusion for 5 Days Every 3 Weeks With Fixed Dosing Recommendations
2001
Journal of Clinical Oncology
B.C. Goh
Mark J. Ratain
Donna Bertucci
Robert P. Smith
Sridhar Mani
N. J. Vogelzang
Richard L. Schilsky
M. Hutchison
M. Smith
S. Averbuch
E. Douglass
Show All
Source
Cite
Save
Citations (30)
Phase I S tudy o f Z D9331 o n S hort D aily I ntravenous B olus Infusion f or 5 D ays E very 3 W eeks W ith F ixed D osing Recommendations
2001
Mark J. Ratain
Donna Bertucci
Robert P. Smith
Sridhar Mani
M. Hutchison
M. Smith
S. Averbuch
E. Douglass
Show All
Source
Cite
Save
Citations (0)
A fixed-dose phase I study of ZD9331, a novel non-polyglutamated inhibitor of thymidylate synthase, in patients with refractory cancer
1999
European Journal of Cancer
Donna Bertucci
Mark J. Ratain
Robert A. Smith
Sridhar Mani
Nicholas J. Vogelzang
Richard L. Schilsky
B.C. Goh
M. Smith
E. Douglass
Show All
Source
Cite
Save
Citations (5)
1